Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
- PMID: 20347281
- DOI: 10.1016/j.clon.2010.02.011
Review of testing and use of adjuvant trastuzumab across a cancer network--are we treating the right patients?
Abstract
This review of practice assessed all early breast cancer patients diagnosed over 12 months to determine the frequency of human epidermal growth factor receptor 2 (HER2) positivity and trastuzumab use. The frequency of HER2 positivity in routine practice (185/1319; 14%) was less than expected. A significant proportion of patients (56/185; 30%) did not receive trastuzumab, largely due to concerns about chemotherapy tolerability.
Copyright 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
Comment in
-
HER2 testing, adjuvant trastuzumab use and results. Our experience in South Wales.Clin Oncol (R Coll Radiol). 2010 Dec;22(10):894. doi: 10.1016/j.clon.2010.07.003. Epub 2010 Aug 13. Clin Oncol (R Coll Radiol). 2010. PMID: 20708911 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous